ClinicalTrials.gg
Not yet recruitingNCT07277712Updated Dec 11, 2025

A Study to Evaluate the Pharmacokinetics and Food-effect of IN-M00002 Tablet in Healthy Adult Volunteers

A Phase 1 interventional study of Tegoprazan and Naproxen in Healthy Volunteer, sponsored by HK inno.N Corporation. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-11.

Sponsored by HK inno.N Corporation · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Study summary

This study aims to evaluate the pharmacokinetic (PK) following administration of IN-M00002 tablet and co-administration of tegoprazan and naproxen, and to evaluate food-effect of IN-M00002 tablet in healthy adult volunteers

Read the detailed description

A randomized, open-label, crossover study

[Part A] To evaluate and compare the pharmacokinetic and safety of co-administration of tegoprazan and naproxen versus administration of IN-M00002 tablet in healthy adult volunteers

[Part B] To evaluate the effects of food on the pharmacokinetic and safety of IN-M00002 tablet in healthy adult volunteers

02

Conditions studied

  • Healthy Volunteer

Keywords

  • pharmacokinetic
  • food-effect
03

In context

Lead sponsor

HK inno.N Corporation is the lead sponsor of 104 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult aged ≥ 19 and ≤ 55 year-old at screening
  • (BMI) ≥ 19.0 kg/m2 and ≤ 27.0 kg/m2 with a body weight ≥ 45 kg at screening
  • Those determined to be eligible for this study based on the findings of screening such as clinical laboratory tests (hematological test, blood chemistry test, blood coagulation test, urinalysis, test for viruses/bacteria, etc.), vital signs, and (ECG) which are performed by the investigator according to the properties of medicines
  • Those who have fully understood this clinical trial via detailed explanation, were willing to voluntarily participate in this study, and agreed to give written prior to the screening
  • Those with a capability/willingness to participate throughout the study

Exclusion criteria

Exclusion Criteria:

  • Medical history or evidence of blood, renal, endocrine, respiratory, gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurological, musculoskeletal, oncological, or immune disease (except for history of simple dental treatment such as tartar, impacted teeth, and third molar teeth)
  • Previous history of gastrointestinal disease (esophageal disease such as esophageal achalasia or esophageal stricture, inflammatory bowel disease (Crohn's disease, ulcerative colitis)) or surgery (except for simple appendectomy, hernia surgery, tooth extraction, etc.) which may affect drug absorption
  • Sitting systolic blood pressure \< 90 mmHg or ≥ 140 mmHg or diastolic blood pressure \< 60 mmHg or ≥ 90 mmHg at screening
  • Following findings of clinical laboratory tests:

    • or AST value > twice the (ULN)
  • History of periodic alcohol consumption exceeding 210 g/week within 6 months prior to screening (beer (5%) 1 glass (250 mL) = 10 g, soju (20%) 1 glass (50 mL) = 8 g, wine (12%) 1 glass (125 mL) = 12 g)
  • Has taken any other product within 6 months prior to the first dose of investigational product
  • History of serious alcohol or drug misuse and abuse within 1 year prior to screening
  • Administration of drugs known to markedly induce or inhibit drug metabolizing enzymes within 30 days prior to the first dose of the investigational product
  • Daily use of ≥ 20 cigarettes within 6 months prior to screening
  • Administration of a prescription or non-prescription drug within 10 days prior to the first dose of the investigational product
  • Whole blood donation within 2 months prior to the first dose of the investigational product or apheresis donation within 1 month prior to the first dose of the investigational product
  • Subjects who received a blood transfusion within 1 month prior to the first dose of the investigational product
  • Those who may be put at an increased risk due to the administration of the investigational product and study participation or have a severe acute/chronic medical or mental condition which may interfere with the interpretation of study results
  • Subjects with a history of (e.g., asthma, rhinitis, nasal polyps, urticaria, or allergic reactions) to the components of tegoprazan or naproxen, benzimidazole derivatives, aspirin, or other non-steroidal anti-inflammatory drugs (including COX-2 inhibitors)
  • Subjects currently receiving medications containing atazanavir, nelfinavir, or rilpivirine
  • Women with a positive pregnancy test, pregnant, or breastfeeding
  • Subjects are unable to use a highly effective method of (e.g., correctly placed intrauterine device(IUD), sterilization surgery (vasectomy, tubal ligation, etc.))
  • Subjects unable to consume a high-fat diet provided during Part B of the clinical trial
  • Subjects who are considered ineligible to participate in this study at the discretion of the investigator
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
74 participants (estimated)

Study arms

  • Experimental
    Part A: Sequence 1 (Treatment A - Treatment B)

    Period 1: Single dose of tegoprazan 25 mg QD in combination with naproxen 500 mg BID Period 2: Single dose of IN-M00002 tablet BID

    Drug: Tegoprazan · Drug: Naproxen · Drug: IN-M00002

  • Experimental
    Part A: Sequence 2 (Treatment B - Treatment A)

    Period 1: Single dose of IN-M00002 tablet BID Period 2: Single dose of tegoprazan 25 mg QD in combination with naproxen 500 mg BID

    Drug: Tegoprazan · Drug: Naproxen · Drug: IN-M00002

  • Experimental
    Part B: Sequence 1 (Treatment C - Treatment D)

    Period 1: Single dose of IN-M00002 tablet QD under fasted conditions Period 2: Single dose of IN-M00002 tablet QD under fed conditions

    Drug: IN-M00002

  • Experimental
    Part B: Sequence 2 (Treatment D - Treatment C)

    Period 1: Single dose of IN-M00002 tablet QD under fed conditions Period 2: Single dose of IN-M00002 tablet QD under fasted conditions

    Drug: IN-M00002

Interventions

  • Tegoprazan 25 mg QD

    Also known as: K-CAB

  • Naproxen 500 mg BID

    Also known as: Naxen-F

  • DrugIN-M00002

    IN-M00002 tablet QD

  • DrugIN-M00002

    IN-M00002 tablet BID

06

What researchers measure

Primary outcomes

  1. AUCt of tegoprazan

    Area under the plasma concentration-time curve from the time of dosing to the time of the last measurable concentration

    Time frame: Up to 48 hours

  2. AUCt of naproxen

    Area under the plasma concentration-time curve from the time of dosing to the time of the last measurable concentration

    Time frame: Up to 72 hours

  3. Cmax of tegoprazan

    Maximum plasma concentration of tegoprazan

    Time frame: Up to 48 hours

  4. Cmax of naproxen

    Maximum plasma concentration of naproxen

    Time frame: Up to 72 hours

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2025; primary completion for May 2026, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2025
First posted
Dec 11, 2025
StartEst.
Dec 27, 2025
Primary completionEst.
May 30, 2026
CompletionEst.
Sep 30, 2026
Last update
Dec 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07277712
Responsible party
Sponsor
First posted
Dec 11, 2025
Start date
Dec 27, 2025 (estimated)
Primary completion
May 30, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Dec 11, 2025

Study contacts

Seung Hee Jung, PhD
Contact
shee.jung@inno-n.com
+82-31-5176-4653
Eun Ji Kim
Contact
eunji.kim24@inno-n.com
+82-31-5176-4652
Seol Ju Moon, MD, Ph.D
principal investigator · Clinical Pharmacology Center, Jeonbuk National University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion